SCIESCOPUSQ4
Onkourologiya
ABV-PRESS PUBL HOUSE, Russian Federation
Onkourologiya is an academic journal published by ABV-PRESS PUBL HOUSE (Russian Federation). Identifiers: ISSN 1726-9776, eISSN 1996-1812. Indexed in SCIE, SCOPUS. Metrics: JIF 0.1, CiteScore 0.4, SJR 0.116, SNIP 0.10. Subject areas: ONCOLOGY. tlooto lists 80 papers from this journal.
CiteScore
0.40
Scopus citation metric
SJR
0.116
SCImago rank
SNIP
0.10
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- 1726-9776
- eISSN
- 1996-1812
- Abbreviation
- ONKOUROLOGIYA
- Publisher
- ABV-PRESS PUBL HOUSE
- Country
- Russian Federation
Web of Science categories
No Web of Science category data available.
Scopus ASJC categories
2727 Nephrology2730 Oncology2741 Radiology2746 Surgery2748 Urology
Papers in this journal
Recent papers
- Genetic susceptibility to bladder cancer
2026
- Current problems in epidemiology, diagnosis and treatment of testicular cancer
2026
- The Leningrad Regional Clinical Hospital’s own experience of treating non-clear cell renal cell carcinoma with a combination of lenvatinib and pembrolizumab
2026
- Russian radiopharmaceutical Radium chloride, <sup>223</sup>Ra: first year of use in Russia. Real practice, efficacy, and safety profile. Possibilities of combination therapy
2026 · 1 citations
- Efficacy of atezolizumab in patients resistant to platinum-based chemotherapy. Results of the AURORA-RU Study: Atezolizumab in UROthelial cancer: Real-world Analysis of RUssia
2026
Most cited papers
- Neoadjuvant combination drug therapy in treatment of patients with muscle-invasive bladder cancer
2025 · 1 citations
- Multimodal treatment of oligometastatic cancer of ectopic intrathoracic kidney with Bochdalek’s hernia: сlinical observation and literature review
2025 · 1 citations
- Therapy with a protein-peptide complex from embryonic stem cells as a method of reducing nephrotoxic effect of chemotherapy drug cisplatin
2025 · 1 citations
- Expanding indications for sodium fumarate anti-hypoxia infusion solution in kidney cancer surgery: literature review
2025 · 1 citations
- Real-world outcomes of lenvatinib plus pembrolizumab in intermediateand poor-risk metastatic renal cell carcinoma
2025 · 1 citations